Navigation Links
Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
Date:10/4/2007

Lead Compound Produces Significant LDL-Cholesterol Reduction and Weight

Loss When Combined with Zetia(R) in Hypercholesterolemic Patients

BRIDGEWATER, N.J., Oct. 4 /PRNewswire/ -- Aegerion Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the treatment of cardiovascular and metabolic diseases, today announced final results of Phase II clinical trials involving its lead cholesterol management compound, an MTP-inhibitor, AEGR-733 either alone or in combination with ezetimibe (brand name: Zetia(R)*). The data were presented in two posters at the XVI International Symposium on Drugs Affecting Lipid Metabolism (DALM) (October 4-7, 2007, New York, NY), jointly sponsored by the Weill Cornell Medical College (New York, NY) and the Giovanni Lorenzini Medical Foundation (Milan, Italy and Houston, TX).

In the study measuring LDL-cholesterol (LDL-C, or "bad cholesterol") reduction, patients treated with a combination 10 mg of ezetimibe and 10 mg AEGR-733 experienced LDL-C reductions of 46%. Patients treated with 10 mg of ezetimibe alone experienced a 20% reduction in LDL-C levels. Significantly greater reductions in total cholesterol, non-HDL-cholesterol, Lp(a), and apoB were observed in the group receiving combined AEGR-733 and ezetimibe. There was no difference in the rate of discontinuations between the groups treated with AEGR-733 plus ezetimibe versus those treated with ezetimibe alone.

In a separate analysis of these data, the ability of AEGR-733 alone or in combination with ezetimibe was assessed for its ability to cause weight loss. Over the course of this study, patients were counseled on a low fat/low cholesterol diet but with no emphasis on total calories or weight reduction. Drug treatment consisted of ezetimibe alone (10 mg), AEGR-733 in escalating doses at 5 mg, then 7.5 mg, then 10 mg, or a combination of the two drugs for 12 weeks. Weight was monitored over the course of the study.

By 12 weeks, subjects rec
'/>"/>

SOURCE Aegerion Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
2. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
3. Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data on Molecular Imaging Pharmaceutical for Prostate Cancer
4. Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data at Society Of Nuclear Medicine 2007 Annual Meeting
5. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
6. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
7. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
8. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
9. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
10. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
11. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... 3, 2015  UnaliWear announces the market preview of ... seniors that guards against wandering and provides support for ... wearable – the Kanega watch ( http://www.UnaliWear.com ) – ... an easy speech interface rather than buttons, use cellular ... input. The watch goes wherever the ...
(Date:3/3/2015)... -- American Biosurgical, LLC ("ABI") ( www.americanbiosurgical.com ) a ... in the design, development and production of innovative ... device companies has announced the acquisition of MTI ... cable manufacturer based in North Carolina.  The new ... name MTI Medical Cables.  The ...
(Date:3/3/2015)... March 3, 2015  Michigan brothers Dominique Larkin , ... arrhythmogenic right ventricular dysplasia, or ARVD, a disease that causes ... death among young athletes. In 2007, doctors discovered ... game. They later tested Dominique and found his "condition was ... 19, 2015 story in The Ann Arbor News , ...
Breaking Medicine Technology:UnaliWear's Wearable For Seniors Extends Independence With Advanced Technology 2American Biosurgical Acquires MTI Corporation 2Younger of 2 Brothers on the SynCardia Total Artificial Heart Gets a Donor Heart Transplant 2Younger of 2 Brothers on the SynCardia Total Artificial Heart Gets a Donor Heart Transplant 3
(Date:3/4/2015)... Professionals with disabilities are eager to work, technologically savvy ... a new Think Beyond the Label survey. , In ... disabilities , respondents also say they use and would ... are geared to people with disabilities, to help them ... job search tools are used by nearly all job ...
(Date:3/4/2015)... 2015 Nurses, healthcare professionals and the ... Nurses Association (ACNA) to learn about why cannabis is ... of illnesses and conditions. The one-day continuing education (CE) ... offered on April 1 or April 2 at Aloft ... by the Ohio Nurses Association (OBN-001-91), an accredited approver ...
(Date:3/3/2015)... Bar, Calif. (PRWEB) March 03, 2015 ... leading provider of enterprise Time and Attendance / ... successfully migrated to NOVAtime SaaS Workforce Management ... its time and attendance processes. , Since ... those with developmental disabilities with the best quality ...
(Date:3/3/2015)... 03, 2015 Today, Steve Weatherford, current ... Seahawks wide receiver, announced the donation of their brains ... Brain Injury Awareness Month. In an effort to raise ... importance of brain health, Rice and Weatherford spoke of ... need to make brain health a priority to avoid ...
(Date:3/3/2015)... March 03, 2015 The Rheumatology ... expectation of excellence in care and safe practice for ... of the RNS that biologic infusions are administered in ... direct supervision of a registered nurse (RN), as defined ... anaphylaxis can occur in patients receiving these medications during ...
Breaking Medicine News(10 mins):Health News:Job Seekers with Disabilities Seek Targeted Outreach from Employers and Online Job Search Tools, says New Think Beyond The Label Survey 2Health News:Job Seekers with Disabilities Seek Targeted Outreach from Employers and Online Job Search Tools, says New Think Beyond The Label Survey 3Health News:American Cannabis Nurses Association Announces Speaker Lineup for Educational Seminar in Cleveland 2Health News:American Cannabis Nurses Association Announces Speaker Lineup for Educational Seminar in Cleveland 3Health News:Innovative Services, Inc. Successfully Migrates to Cloud-Based NOVAtime Workforce Management Solution to Support Growth and Improve Payroll Processing Time 2Health News:Innovative Services, Inc. Successfully Migrates to Cloud-Based NOVAtime Workforce Management Solution to Support Growth and Improve Payroll Processing Time 3Health News:Steve Weatherford and Sidney Rice Reveal Donation for Brain Injury Awareness Month 2Health News:Administration of Biologic Infusions: A Position Statement of the Rheumatology Nurses Society 2
... identified an unexpected molecular marker that predicts how ... Triple-negative breast cancers --which do not express ... and do not have Her2/neu overexpression or amplification-- ... disease and cannot be treated with endocrine or ...
... By Amanda Gardner HealthDay Reporter , WEDNESDAY, ... early stage prostate cancer, those who have the prostate gland ... a "watchful waiting" approach, according to a new long-term study ... to be practice-changing, said Dr. Richard E. Greenberg, chief of ...
... HealthDay Reporter , WEDNESDAY, May 4 (HealthDay News) -- ... rectify ventricular fibrillation, a severely abnormal heart rhythm, in ... death, according to new research. The device, called ... in Europe and is undergoing review by the U.S. ...
... In three new studies published in the May issue of ... Medicine researchers reveal the staggering economic impact of toxic chemicals ... to mandate testing of new chemicals and also those already ... of Preventive Medicine and Pediatrics at Mount Sinai School of ...
... and DES MOINES, Iowa, May 4, 2011 The Donald ... million grant from the Howard G. Buffett Foundation to bring ... grant will help fund the completion of the development of ... who depend upon sorghum as their staple diet. DuPont ...
... The Translational Genomics Research Institute (TGen) has licensed ... tumors by modifying the actions of proteins. Today,s ... To move laboratory discoveries more rapidly into therapeutics that ... The drug, ONCO-101, is being licensed to Syracuse, ...
Cached Medicine News:Health News:Gene expression predicts chemotherapy sensitivity of triple-negative breast cancer 2Health News:Aggressive Treatment May Be Beneficial for Early Prostate Cancer 2Health News:Aggressive Treatment May Be Beneficial for Early Prostate Cancer 3Health News:New Defibrillator Shows Promise in Small Study 2Health News:Estimated costs of environmental disease in children at $76.6 billion per year 2Health News:Estimated costs of environmental disease in children at $76.6 billion per year 3Health News:Grant funds next phase in bringing healthier sorghum closer to underserved communities 2Health News:TGen licenses first drug for patient use in clinical care 2
For use in implant resection arthroplasty of the trapeziometacarpal joint in cases of rheumatoid, degenerative or post-traumatic arthritis....
... Hand Implant System utilizes the same proven ... replacements. The SR™ Hand Implant System ... prostheses including minimal bone resection, surface replacement ... surfaces, retention and/or repositioning of the ligamentous ...
The NeurOptics Pupillometer is a portable instrument used to measure pupils to screen candidates for refractive procedures and other ophthalmic applications....
... TrinicaTM anterior cervical plate system features ... preferences and patient needs. Trinica system gives ... to each patient's unique anatomy. Flexibility is ... system-from plate design and the innovative Secure-TwistTM ...
Medicine Products: